

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Two issues were raised during consultation:

Patients with limited mobility might benefit greatly from dabigatran's lack of monitoring requirements

Patients with specific religious or cultural beliefs or who are intolerant or unable to comply with monitoring requirements of VKAs might prefer dabigatran as heparins can be of porcine origin.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Neither of these was seen as potential equality issues as alternative treatments exist that do not require monitoring and which are not of porcine origin.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No change has been made to the draft scope as a result of the issues raised.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

None has been identified.

**Approved by Associate Director (name):** ...Janet Robertson

**Date:** 02 December 2013